Trial Profile
Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced (Unresectable or Metastatic) Melanoma: A Multicentric, Observational Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Aug 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 24 Apr 2018 New trial record